Kestra Advisory Services’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Kestra Advisory Services’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,068	Closed	-$23K	–	2234
2021 Q3	$23K	Buy	+2,068	New	+$26K	﹤0.01%	2104
2021 Q2	–	Sell	-1,170	Closed	-$31K	–	2045
2021 Q1	$31K	Buy	+1,170	New	+$53.2K	﹤0.01%	1839

Other funds holding EVFM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Kestra Advisory Services's EVFM Position: Q4 2021 in Review

Kestra Advisory Services sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2021, closing a stake of 2,068 shares — an estimated $23K sold.

Kestra Advisory Services first reported a position in EVFM in Q1 2021 and held it in 2 quarters. The position peaked at $31K in Q1 2021. 62 funds tracked by Wall St. Rank hold EVFM as of Q4 2021.

Kestra Advisory Services reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Kestra Advisory Services sold 2,068 Evofem Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $23K.
Kestra Advisory Services first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
Kestra Advisory Services's Evofem Biosciences, Inc. Common Stock position peaked at $31K in Q1 2021.
62 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2021.

Based on Kestra Advisory Services's 13F filing for Q4 2021, filed 20 Jan 2022.